Medical Device Quality Agreements
OEM Responsibilities

An OEM project can agree its formulation, carton design and delivery target while leaving a crucial question unanswered: who decides whether a proposed change is acceptable? When the supplier changes a packaging component or the brand owner requests new wording, “both parties will cooperate” gives little operational guidance.

A quality agreement should translate that cooperation into decisions, evidence and named handoffs. It supports the OEM project plan rather than replacing the product specification or commercial contract.

Which responsibilities belong in a medical device quality agreement?

Start with the decisions that can affect product identity, evidence or release status. For each, distinguish the person who performs the activity from the function that reviews or authorizes the outcome. The same organization may hold several roles, but the agreement should say so clearly.

ISO 13485 provides a quality-management framework for medical devices. For applicable US device operations, FDA states that the QMSR took effect on February 2, 2026, incorporating ISO 13485:2016 by reference. Those sources establish context; the table below is an editorial tool for structuring a project discussion, not a substitute for the applicable requirements.

Activity	Specify in the agreement	Evidence at the handoff
Product specification	Approved version and owner of revisions	Controlled specification reference
Materials or process change	Notice, impact review and decision authority	Change description and assessment
Artwork	Content approval and print-release ownership	Approved master and revision
Lot release	Responsible function and information supplied	Identified release documentation
Nonconforming shipment	Hold status, investigation and disposition route	Lot-level discrepancy record
Complaint	Intake contact, escalation and investigation owner	Complaint reference and follow-up record
Traceability	Records each party retains and can retrieve	Lot, quantity and distribution links

Do not use the table to transfer a legal responsibility by assumption. Identify the actual manufacturer, brand owner, importer and distributor roles for the product and market before finalizing the allocation.

How specific should change notification be?

Specific enough that the parties can recognize a relevant change and know what happens before implementation. “Notify significant changes” is weak if nobody has agreed what significant means for the project.

Discuss changes to the product configuration, manufacturing location, relevant suppliers, process, packaging, labelling and supporting evidence. Then state how proposed changes are described, who assesses them, whether approval is needed before implementation and how affected stock or orders are identified.

The agreement should also handle an urgent situation in which a normal communication route is unavailable. List a backup contact and the escalation path. A contact name without an accountable function becomes obsolete when staff change.

What records should the buyer be able to obtain?

Define the information needed for the buyer’s own duties and purchasing decisions, including how it can be accessed. Some records may be shared routinely; others may require controlled review. Make that distinction before an urgent request.

For example, a brand owner may need the approved artwork master and a lot-level shipment record without receiving every confidential manufacturing instruction. The quality agreement can define document references, access arrangements and the route for technical questions. Avoid promising unrestricted disclosure that the supplier cannot actually provide.

Agree how records remain retrievable if the commercial relationship ends. Product complaints and traceability questions may continue after the final purchase order, so a termination clause should not leave the evidence path undefined.

How do you test whether the agreement works?

Walk through a realistic scenario before signing. Suppose a shipment arrives with a different packaging revision and one unreadable lot label. Ask each party to describe its first action, the record created, who can place stock on hold and who makes the final disposition.

If the answers conflict, revise the agreement or procedure. If both parties point to the other as the decision owner, the gap is already visible without waiting for an actual incident. Use a second scenario involving an urgent complaint to test contact availability and escalation.

The resulting agreement should be short enough to use and detailed enough to resolve these handoffs. Keep version control, named roles and linked procedures current. A well-indexed agreement that people can follow is more valuable than a long template whose responsibilities were never adapted to the project.

For concrete handoffs, connect the agreement to private label artwork approval and the review of finished-device biocompatibility evidence. These records resolve different questions and should retain separate owners and revision histories.